<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36929044</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-7799</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical and experimental nephrology</Title><ISOAbbreviation>Clin Exp Nephrol</ISOAbbreviation></Journal><ArticleTitle>Profiling of kidney involvement in systemic lupus erythematosus by deep learning using the National Database of Designated Incurable Diseases of Japan.</ArticleTitle><Pagination><StartPage>519</StartPage><EndPage>527</EndPage><MedlinePgn>519-527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10157-023-02337-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Kidney involvement frequently occurs in systemic lupus erythematosus (SLE), and its clinical manifestations are complicated. We profiled kidney involvement in SLE patients using deep learning based on data from the National Database of Designated Incurable Diseases of Japan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed the cross-sectional data of 1655 patients with SLE whose Personal Clinical Records were newly registered between 2015 and 2017. We trained an artificial neural network using clinical data, and the extracted characteristics were evaluated using an autoencoder. We tested the difference of population proportions to analyze the correlation between the presence or absence of kidney involvement and that of other clinical manifestations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data of patients with SLE were compressed in a feature space in which the anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody titer, antinuclear antibody titer, or white blood cell count contributed significantly to distinguishing patients. Many SLE manifestations were accompanied by kidney involvement, whereas in a subgroup of patients with high anti-dsDNA antibody titers and low antinuclear antibody titers, kidney involvement was positively and negatively correlated with hemolytic anemia and inflammatory manifestations, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although there are various combinations of SLE manifestations, our study revealed that some of them are specific to kidney involvement. SLE profiles extracted from the objective analysis will be useful for categorizing SLE manifestations.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8186-094X</Identifier><AffiliationInfo><Affiliation>Reverse Translational Research Project, Center for Rare Disease Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan. t-kimura@nibiohn.go.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Rare Disease Resource Library, Center for Rare Disease Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan. t-kimura@nibiohn.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Hidekazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshino</LastName><ForeName>Mitsuaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Rare Disease Resource Library, Center for Rare Disease Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakate</LastName><ForeName>Ryuichi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Rare Disease Resource Library, Center for Rare Disease Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Shoichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narita</LastName><ForeName>Ichiei</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiromura</LastName><ForeName>Keiju</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JPMH20FC1045</GrantID><Agency>Ministry of Health, Labour and Welfare</Agency><Country/></Grant><Grant><GrantID>JPMH21FC1018</GrantID><Agency>Ministry of Health, Labour and Welfare</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Clin Exp Nephrol</MedlineTA><NlmUniqueID>9709923</NlmUniqueID><ISSNLinking>1342-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="Y">Deep Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep learning</Keyword><Keyword MajorTopicYN="N">Designated incurable diseases</Keyword><Keyword MajorTopicYN="N">Kidney involvement</Keyword><Keyword MajorTopicYN="N">National database</Keyword><Keyword MajorTopicYN="N">Profiling</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>All authors declared no competing interests regarding this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36929044</ArticleId><ArticleId IdType="pmc">PMC10191896</ArticleId><ArticleId IdType="doi">10.1007/s10157-023-02337-x</ArticleId><ArticleId IdType="pii">10.1007/s10157-023-02337-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012;64(2):159&#x2013;168. doi: 10.1002/acr.20683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20683</ArticleId><ArticleId IdType="pubmed">22052624</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Malvar A, Song H, Shapiro J, Mejia-Vilet JM, Ayoub I, et al. Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis. Kidney Int. 2022;102(4):845&#x2013;865. doi: 10.1016/j.kint.2022.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.05.033</ArticleId><ArticleId IdType="pmc">PMC9613357</ArticleId><ArticleId IdType="pubmed">35788359</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789&#x2013;796. doi: 10.1016/j.kint.2017.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugas E, Nochy D, Huong DLT, Duhaut P, Beaufils H, Caudwell V, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002;13(1):42&#x2013;52. doi: 10.1681/ASN.V13142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V13142</ArticleId><ArticleId IdType="pubmed">11752020</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber C, Herzenberg A, Aghdassi E, Su J, Lou W, Qian G, et al. Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol. 2012;7(5):757&#x2013;764. doi: 10.2215/CJN.02870311.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02870311</ArticleId><ArticleId IdType="pmc">PMC3338275</ArticleId><ArticleId IdType="pubmed">22442181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi H, Sugiyama H, Sato H, Yokoyama H, Maruyama S, Mukoyama M, et al. A nationwide analysis of renal and patient outcomes for adults with lupus nephritis in Japan. Clin Exp Nephrol. 2022;26(9):898&#x2013;908. doi: 10.1007/s10157-022-02232-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-022-02232-x</ArticleId><ArticleId IdType="pubmed">35556186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollak VE, Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic Lupus Erythematosus. J Lab Clin Med. 1964;63:537&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">14155443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Dasgupta A, Ward MM. Risk of End-stage renal disease in patients with lupus nephritis, 1971&#x2013;2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432&#x2013;1441. doi: 10.1002/art.39594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39594</ArticleId><ArticleId IdType="pmc">PMC5071782</ArticleId><ArticleId IdType="pubmed">26815601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdiyev N, Lahann J, Emrich A, Enke D, Fettke P, Loos P. Time series classification using deep learning for process planning: a case from the process industry. Procedia Comput Sci. 2017;114:242&#x2013;249. doi: 10.1016/j.procs.2017.09.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.procs.2017.09.066</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira J, Silverira M. Unsupervised Anomaly Detection in Energy Time Series Data Using Variational Recurrent Autoencoders with Attention. In: 2018 17th IEEE International Conference on Machine Learning and Applications (ICMLA). 2018:1275&#x2013;82.</Citation></Reference><Reference><Citation>Kieu T, Yang B, Guo C, Jensen CS. Outlier Detection for Time Series with Recurrent Autoencoder Ensembles. In: Proceedings of the Twenty-Eighth International Joint Conference on Artificial Intelligence. 2019:2725&#x2013;32.</Citation></Reference><Reference><Citation>Kimura T, Yamamoto R, Yoshino M, Sakate R, Imai E, Maruyama S, et al. Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS) Clin Exp Nephrol. 2022;26(12):1170&#x2013;1179. doi: 10.1007/s10157-022-02256-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-022-02256-3</ArticleId><ArticleId IdType="pmc">PMC9668942</ArticleId><ArticleId IdType="pubmed">35962244</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez Maimo L, Perales Gomez AL, Garcia Clemente FJ, Gil Perez M, Martinez PG. A self-adaptive deep learning-based system for anomaly detection in 5G networks. IEEE Access. 2018;6:7700&#x2013;7712. doi: 10.1109/ACCESS.2018.2803446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ACCESS.2018.2803446</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoda S, Murata N. Transport analysis of infinitely deep neural network. J Mach Learn Res. 2019;20(1):31&#x2013;82.</Citation></Reference><Reference><Citation>Font J, Cervera R, Ramos-Casals M, Garcia-Carrasco M, Sents J, Herrero C, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum. 2004;33(4):217&#x2013;230. doi: 10.1053/S0049-0172(03)00133-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/S0049-0172(03)00133-1</ArticleId><ArticleId IdType="pubmed">14978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurencak R, Fritzler M, Tyrrell P, Hiraki L, Benseler S, Silverman E. Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations. J Rheumatol. 2009;36(2):416&#x2013;421. doi: 10.3899/jrheum.080588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.080588</ArticleId><ArticleId IdType="pubmed">19208567</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmun Rev. 2013;12(7):784&#x2013;791. doi: 10.1016/j.autrev.2013.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2013.02.001</ArticleId><ArticleId IdType="pubmed">23462431</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou KA, Dall Era M, Aranow C, Anders HJ. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022;13:980079. doi: 10.3389/fimmu.2022.980079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.980079</ArticleId><ArticleId IdType="pmc">PMC9472122</ArticleId><ArticleId IdType="pubmed">36119023</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie RA, Bruce DS, Vital EM, Dall'Era M, Maho E, et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. The Lancet Rheumatol. 2022;4(4):e282&#x2013;e292. doi: 10.1016/S2665-9913(21)00317-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00317-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton ZC, Kale DC, Elkan E, Wetzel R. Learning to Diagnose with LSTM Recurrent Neural Networks. arXivorg. 2017; arXiv:1511.03677.</Citation></Reference><Reference><Citation>Kimura T, Hesaka A, Isaka Y. d-Amino acids and kidney diseases. Clin Exp Nephrol. 2020;24(5):404&#x2013;410. doi: 10.1007/s10157-020-01862-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-020-01862-3</ArticleId><ArticleId IdType="pmc">PMC7174270</ArticleId><ArticleId IdType="pubmed">32112266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesaka A, Yasuda K, Sakai S, Yonishi H, Namba-Hamano T, Takahashi A, et al. Dynamics of D-serine reflected the recovery course of a patient with rapidly progressive glomerulonephritis. CEN Case Rep. 2019;8(4):297&#x2013;300. doi: 10.1007/s13730-019-00411-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13730-019-00411-6</ArticleId><ArticleId IdType="pmc">PMC6820815</ArticleId><ArticleId IdType="pubmed">31359345</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>